Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. The company focuses on its proprietary POZ drug delivery technology designed to modify existing drugs and novel drug candidates to improve efficacy and safety profiles across multiple modalities including small molecules RNA-based therapeutics and antibody-drug conjugates. The POZ technology is…
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. The company focuses on its proprietary POZ drug delivery technology designed to modify existing drugs and novel drug candidates to improve efficacy and safety profiles across multiple modalities including small molecules RNA-based therapeutics and antibody-drug conjugates. The POZ technology is based on a synthetic water-soluble low viscosity polymer called poly(2-oxazoline) engineered to provide greater control in drug loading and precision in the rate of drug release via easy-to-administer long-acting subcutaneous injection.
Serina Therapeutics Inc generates revenue primarily through licensing agreements partnerships and potential future commercialization of its product candidates. The company has entered into licensing deals such as a non-exclusive license agreement with Pfizer for POZ polymer technology in lipid nanoparticle drug delivery formulations which includes upfront payments milestone payments and royalties on net sales. Revenue may also arise from out-licensing co-development or other partnership arrangements for applications of the POZ platform in areas such as infectious disease vaccines cancer immunology and gene therapy. The company does not currently have commercial products on the market and relies on research and development funding and partnership income.
The company operates through the following segments:
Serina Therapeutics Inc operates in the competitive field of drug delivery technologies with a focus on polymer-based platforms. The company differentiates itself from established technologies like polyethylene glycol PEGylation by offering advantages such as simpler and safer synthesis using inexpensive starting materials non-immunogenic properties higher drug loading capacity no tissue accumulation and renal clearance without metabolism. These features position POZ as a potential alternative to PEG in applications requiring repeated dosing and long-term use particularly in vaccines and chronic disease treatments where anti-PEG immunity is a growing concern.
Serina Therapeutics Inc serves patients and healthcare providers in the treatment of neurological diseases with a primary focus on Parkinson’s disease. The company’s product candidates are designed for subcutaneous administration in outpatient or home settings targeting individuals with early to advanced Parkinson’s disease who experience motor fluctuations and levodopa-induced dyskinesia. The company also aims to serve partners in the vaccine and gene therapy sectors seeking alternatives to PEG-lipids in lipid nanoparticle formulations for infectious disease vaccines cancer immunology and other therapeutic applications.